Skip to main content
SpringerLink
Log in

Health Economics, Cost-Effectiveness, and Glaucoma Care

  • Chapter
Glaucoma

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albright CD, Schuman SG, Netland PA (2002) Usage and cost of laser trabeculoplasty in the United States. Ophthalmic Surg Lasers 33:334–336

    PubMed  Google Scholar 

  2. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13:397–409

    Article  PubMed  CAS  Google Scholar 

  3. Boivin JF, McGregor M, Archer C (1996) Cost effectiveness of screening for primary open angle glaucoma. J Med Screening 3:154–163

    CAS  Google Scholar 

  4. Calissendorff BM (2001) Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 79:286–288

    Article  PubMed  CAS  Google Scholar 

  5. Canadian Coordinating Office for Health Technology Assessment (1997) Guidelines for Economic Evaluation of Pharmaceuticals, 2nd edn. Ottawa, Canada

    Google Scholar 

  6. Commonwealth Department of Human Services and Health (1995) Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits. Advisory Committee. Canberra, Australia

    Google Scholar 

  7. Costagliola C, Parmeggiani F, Sebastiuani A (2003). Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 4:1775–1788

    Article  PubMed  CAS  Google Scholar 

  8. Cottle RW, Begg IS (1988) Effectiveness and costs of antiglaucoma medications. J Toxicol Cut Ocular Toxicol 7:283–293

    Google Scholar 

  9. Coyle D, Drummond M (1995) The economic burden of glaucoma in the UK: the need for a farsighted policy. Pharmacoeconomics 7:484–489

    PubMed  CAS  Google Scholar 

  10. De Natale R, Draghi E, Dorigo MT (2004) How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 82:393–396

    Article  PubMed  Google Scholar 

  11. Denis P, Lafuma A, Berdeaux G (2004) Medical predictive factors of glaucoma treatment costs. Glaucoma 13:283–290

    Article  Google Scholar 

  12. Drummond MF, Richardon S, O’Brien BJ et al (1997) Users’ guides to the medical literature, XIII. How to use an article on economic analysis of clinical practice. Are the results of the study valid? J Am Med Assoc 277:1552–155

    Article  CAS  Google Scholar 

  13. Evans RG (2004) A conclusion in search of arguments: economists and the quest for more regressive health care financing. The Yrj Foundation 50th Anniversary Symposium on Incentives and Finance of Health Care System, 9–10 August 2004

    Google Scholar 

  14. Finckler SA (1982) The distinction between cost and charges. Ann Intern Med 96:102–109

    Google Scholar 

  15. Fisher ES, Welch HG (1999): Avoiding the unintended consequences of growth in medical care. How might more be worse? J Am Med Assoc 281:446–453

    Article  CAS  Google Scholar 

  16. Fisher ES, Wennberg DE, Stukel TA et al (2003a) The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med 138:273–287

    PubMed  Google Scholar 

  17. Fisher ES, Wennberg DE, Stukel TA et al (2003b) The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med 138:288–298

    PubMed  Google Scholar 

  18. Fleming C, Whitlock E, Beil T et al (2005) Primary care screening for ocular hypertension and primary open-angle glaucoma. Evidence synthesis 34, contract no. 290-02-0024, Oregon Evidence-Based Practice Center (http://www.ahrq. gov/clinic/uspstf05/glaucoma/glaucsyn.pdf)

    Google Scholar 

  19. Gottlieb LK, Schwartz B, Pauker S (1983) Glaucoma screening. Cost-effectiveness analysis. Surv Ophthalmol 28:206–227

    Article  PubMed  CAS  Google Scholar 

  20. Hawthorne G, Richardson J, Day NA (2001) A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med 33:358–370

    PubMed  CAS  Google Scholar 

  21. Iskedjian M, Walker J, Vicente C et al (2003) Cost of glaucoma in Canada: analyses based on visual field and physician’s assessment. J Glaucoma 12:456–462

    Article  PubMed  Google Scholar 

  22. Johnston K, Kennedy C, Murdoch I et al (2004) The cost-effectiveness of technology transfer using telemedicine. Health Policy Plan 19:302–309

    Article  PubMed  CAS  Google Scholar 

  23. Kobelt G (1999) An observational study and cost simulation model of treatment strategies in patients with OH or POAG: materials, methods, results by country. In: Jösson B, Krieglstein G (eds) Primary open-angle glaucoma. Differences in international treatment patterns and cost. Isis Medical Media, Oxford

    Google Scholar 

  24. Kobelt G (2002) Glaucoma care updates. Health economics, economic evaluation, and glaucoma. J Glaucoma 11:531–539

    Article  PubMed  Google Scholar 

  25. Kobelt G, Jösson L ((1999) Modeling cost of patient management with new topical treatments for glaucoma. Results for France and the UK. Int J Technol Assess Health Care 15:207–219

    Article  PubMed  CAS  Google Scholar 

  26. Kobelt G, Jösson L, Gerdtham UG et al (1998) Direct costs of glaucoma management following initiation of medical therapy. Graefe’s Arch 236:811–821

    CAS  Google Scholar 

  27. Linna M, Taimela E, Apajasalo M et al (2002) Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson’s disease. Expert Rev Pharmacoecon Outcomes Res 2:89–95

    Google Scholar 

  28. Maynard A (2001) Ethics and health care “underfunding”. J Med Ethics 27:223–23

    Article  PubMed  CAS  Google Scholar 

  29. Maynard A (2004) Health economics in the past, the present and the future. The Yrj Foundation 50th Anniversary Symposium on Incentives and Finance of Health Care System, 9–10 August 2004

    Google Scholar 

  30. Maynard A, Kanavos P (2000) Health economics: enevolving paradigm. Health Econ 9:183–190

    Article  PubMed  CAS  Google Scholar 

  31. McGlynn EA (2004) There is no perfect health system. Health Affairs 23:100–103

    Article  PubMed  Google Scholar 

  32. Mick AB, Gonzales S, Dunbar MT et al (2002) A cost analysis of the prostaglandins analogs. Optometry 73:614–619

    PubMed  Google Scholar 

  33. Muir Gray JA (2001) Evidence-based healthcare. How to make health policy and management decisions. Churchill Livingstone, Harcourt Publisher Limited, London

    Google Scholar 

  34. Murray CJ (1994) Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Org 72:429–445

    PubMed  CAS  Google Scholar 

  35. Oostenbrink JB, Rutten-Van Molken MP, Sluyter-Opdenoordt TS (2001) Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 10:184–191

    Article  PubMed  CAS  Google Scholar 

  36. Paikal D, Fei Y, Coleman AL (2002) Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998. Ophthalmology 109:1372–1376

    Article  PubMed  Google Scholar 

  37. Rouland JF, Berdeaux G, Lafuma A (2005) The economic burden of glaucoma and ocular hypertension: implications for patient management. A review. Drugs Aging 22:315–321

    Article  PubMed  Google Scholar 

  38. Stavem K (1999) Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 8:45–54

    Article  PubMed  CAS  Google Scholar 

  39. Sintonen H (2001) The 15D instrument of healthrelated quality of life: properties and applications. Ann Med 33:328–336

    PubMed  CAS  Google Scholar 

  40. Sterman J (2002) All models are wrong: reflections on becoming a systems scientist. System Dyn Rev 18:501–531

    Article  Google Scholar 

  41. Strutton DR, Walt JG (2004) Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 13:221–226

    Article  PubMed  Google Scholar 

  42. Tuck MW, Crick RP (1997) The cost-effectiveness of various modes of screening for primary open angle glaucoma. Ophthal Epidemiol 4:3–17

    Article  CAS  Google Scholar 

  43. Tuulonen A, Ohinmaa A, Alanko H et al (1999) The application of teleophthalmology in examining patients with glaucoma. A pilot study. J Glaucoma 8:367–373

    PubMed  CAS  Google Scholar 

  44. Tuulonen A, Airaksinen PJ, Erola E et al (2003) The Finnish evidence based guideline for glaucoma. Acta Ophthalmol Scand 81:3–18

    Article  PubMed  CAS  Google Scholar 

  45. Tuulonen A (2004) Is more always better? Editorial. Acta Ophthalmol Scand 82:377–379

    Article  PubMed  Google Scholar 

  46. Walt JG, Lee JT (2004) A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma and ocular hypertension. Surv Ophthalmol 49(Suppl 1):S36–S44

    Article  PubMed  Google Scholar 

  47. Williams A (1988) Health economics: the cheerful face of dismal science? In: Culyer AJ, Masyndar (eds) Being reasonable about the economics of health, Edward Elgar, Cheltenham, UK

    Google Scholar 

  48. Williams A (1993). Priorities and research strategy in health economics for the 1990s. Health Econ Quest Editorial 2:295–302

    CAS  Google Scholar 

  49. Vold SD, Riggs WL, Jackimiec J (2002) Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 11:354–358

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Oulu, P.O. Box 5000, FIN-90014, Oulu, Finland

    Anja Tuulonen MD

  2. Department of Public Health, University of Helsinki and FinOHTA, P.O. Box 41, 00014, Finland

    Harri Sintonen PhD

Authors
  1. Anja Tuulonen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harri Sintonen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University of Wuerzburg, Josef-Schneider-Straße 11, 97080, Wuerzburg, Germany

    Franz Grehn MD (Professor and Chairman) (Professor and Chairman)

  2. Department of Ophthalmology, USCF, 10 Kirkham Street, Rm K301, San Francisco, CA, 94143, USA

    Robert Stamper MD (Director of Glaucoma Service) (Director of Glaucoma Service)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tuulonen, A., Sintonen, H. (2006). Health Economics, Cost-Effectiveness, and Glaucoma Care. In: Grehn, F., Stamper, R. (eds) Glaucoma. Essentials in Ophthalmology. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-34773-9_8

Download citation

  • DOI: https://doi.org/10.1007/3-540-34773-9_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-26220-6

  • Online ISBN: 978-3-540-34773-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation